Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer
- PMID: 16619546
Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer
Abstract
Background: Galectin-3 (gal-3) participates in a variety of biological events, including cell adhesion, proliferation, differentiation and apoptosis. The aim of this study was to determine the relationship of gal-3 expression with clinicopathological findings and prognosis in patients with gastric cancer.
Patients and methods: Gal-3 and Ki-67 expressions were assessed by immunohistochemistry in 115 patients with gastric cancer. PCR-single strand conformation polymorphism (SSCP)-sequence analysis and the levels of gal-3 mRNA were also examined.
Results: The present study demonstrated that gal-3 expression was correlated with nodal status, lymphatic inivasion, pathological stage and histological parameters. On the other hand, gal-3 expression did not correlate with the expression of Ki-67. Reduced expression of gal-3 was significantly associated with a poor prognosis and multivariate analysis showed that gal-3 expression was an independent prognostic factor. On PCR-SSCP-sequence analysis, 2 single nucleotide polymorphisms (SNPs) were detected in the gal-3 gene, but none showed mutations.
Conclusion: Reduced gal-3 expression was associated with lymph node metastasis, advanced stage and tumor differentiation in gastric cancer. Gal-3 expression could be a useful prognostic factor in gastric cancer.
Similar articles
-
Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer.J Gastroenterol Hepatol. 2006 Oct;21(10):1596-603. doi: 10.1111/j.1440-1746.2006.04228.x. J Gastroenterol Hepatol. 2006. PMID: 16928223
-
The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.Anticancer Res. 2009 Feb;29(2):703-9. Anticancer Res. 2009. PMID: 19331225
-
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.Ann Surg Oncol. 2009 Jan;16(1):208-19. doi: 10.1245/s10434-008-0214-6. Epub 2008 Nov 14. Ann Surg Oncol. 2009. PMID: 19009246
-
Li-cadherin is inversely correlated with galectin-3 expression in gastric cancer.Dig Dis Sci. 2008 Jul;53(7):1811-7. doi: 10.1007/s10620-007-0080-2. Epub 2007 Nov 13. Dig Dis Sci. 2008. PMID: 17999183
-
Galectin-3 in cancer.Clin Chim Acta. 2014 Apr 20;431:185-91. doi: 10.1016/j.cca.2014.01.019. Epub 2014 Feb 12. Clin Chim Acta. 2014. PMID: 24530298 Review.
Cited by
-
Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer.Surg Today. 2013 Aug;43(8):901-5. doi: 10.1007/s00595-012-0378-3. Epub 2012 Oct 23. Surg Today. 2013. PMID: 23090139
-
Quinoline-Pyrazole Scaffold as a Novel Ligand of Galectin-3 and Suppressor of TREM2 Signaling.ACS Med Chem Lett. 2020 Aug 11;11(9):1759-1765. doi: 10.1021/acsmedchemlett.0c00330. eCollection 2020 Sep 10. ACS Med Chem Lett. 2020. PMID: 32944144 Free PMC article.
-
Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies.Cancer Cell Int. 2018 Nov 3;18:172. doi: 10.1186/s12935-018-0668-y. eCollection 2018. Cancer Cell Int. 2018. PMID: 30410421 Free PMC article.
-
Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation.Clin Exp Immunol. 2008 May;152(2):285-97. doi: 10.1111/j.1365-2249.2008.03618.x. Epub 2008 Mar 10. Clin Exp Immunol. 2008. PMID: 18336593 Free PMC article.
-
The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma.J Cancer Res Clin Oncol. 2012 Jun;138(6):1035-43. doi: 10.1007/s00432-012-1178-2. Epub 2012 Feb 25. J Cancer Res Clin Oncol. 2012. PMID: 22367363
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical